Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07379684 · ClinicalTrials.gov registry record · Phase 1
A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections
A Phase 1 study of Surgical Wound Infection and Traumatic Wound Infection, sponsored by Macro Biologics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 3
- Study locations
NCT07379684: Recruiting Phase 1 study of Surgical Wound Infection and Traumatic Wound Infection, sponsored by Macro Biologics.
NCT07379684 is a Phase 1 study of Surgical Wound Infection and Traumatic Wound Infection that is actively recruiting participants, run by Macro Biologics. The registered enrollment target is 44 participants, below the 923-participant average among 8 other Surgical Wound Infection trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07379684, a Phase 1 study of Surgical Wound Infection and Traumatic Wound Infection, is actively recruiting participants, sponsored by Macro Biologics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are: 1. Is Amicidin-β topical solution safe to test in larger clinical trials? 2. Is Amicidin-β topical solution absorbed into the bloodstream from local wound application? 3. Is Amicidin-β topical solution easy for the surgeon to use? Participants will receive either standard of care alone, or standard of care with intrawound Amicidin-β topical solution for the management of their wound infection. Researchers will compare these two groups (standard of care alone to standard of care with Amicidin-β topical solution) to see if there are any study drug-related adverse effects.
Conditions Studied
Interventions
- DRUG Standard of Care (SOC)
- DRUG Amicidin-β topical solution - 15 mL
- DRUG Amicidin-β topical solution - 50 mL
Study Locations (3)
Idaho
- Snake River Research, PLLC - Idaho Falls
Maryland
- LifeBridge Health - Baltimore
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2026-10-28 |
| Phase | Phase 1 |
What NCT07379684 shows while recruiting
NCT07379684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 923-participant average among 8 other Surgical Wound Infection trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Surgical Wound Infection appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care (SOC) is the first listed.
NCT07379684 reports a single indexed study location in Idaho, Maryland, Ohio.
Frequently Asked Questions
What is clinical trial NCT07379684 about?
NCT07379684 is a clinical study titled "A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections". The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are: 1. Is Amicidin-β topical solution safe to test in larger cli...
What is the current status of trial NCT07379684?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2026-02-02. Estimated completion is 2026-10-28.
What conditions does trial NCT07379684 study?
This clinical trial studies the following conditions: Surgical Wound Infection, Traumatic Wound Infection.
What interventions are being tested in trial NCT07379684?
The interventions under investigation include: Standard of Care (SOC) (DRUG), Amicidin-β topical solution - 15 mL (DRUG), Amicidin-β topical solution - 50 mL (DRUG).
Who is sponsoring clinical trial NCT07379684?
This trial is sponsored by Macro Biologics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07379684 being conducted?
This trial has 3 study locations across Idaho, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgical Wound Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07379684's enrollment target sits among peer trials
44 8th of 8 higher than 1 of 8 other Surgical Wound Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgical Wound Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal
RECRUITING · Phase 3
-
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections
RECRUITING · Phase 3
-
Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System
RECRUITING · NA
-
NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Local Warming of Surgical Incisions
COMPLETED · Phase 3
-
Topical Antibiotic Prophylaxis for Eyelids
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI